Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
SYNDICATED 1 months ago GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’ Webinar details are as follows: Presentation title:Efficacy Data Updates from Novavax’ Protein-based Vaccine CandidateDate:February 2, 2021Time:4:00 pm ETPresenter:Dr. Glenn Novavax announced interim data last week on its protein-based COVID-19 vaccine candidate that demonstrated efficacy of 89.3% in a pivotal Phase 3 clinical trial taking place in the United Kingdom (UK). The data from this UK Phase 3 trial and a South Africa Phase 2b study were the first to demonstrate cl
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
Novavax, Inc.February 2, 2021 GMT
GAITHERSBURG, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced memorandum of understanding with the Canadian government to produce NVX-CoV2373, the Company’s protein-based vaccine candidate against COVID-19 in Canada.
“Since the beginning of the pandemic, our top priority has been the health and safety of all Canadians,” said Prime Minister Justin Trudeau. “Today, we are investing in our biomanufacturing capacity so that we have the made-in-Canada vaccines and treatments we need to protect Canadians, now and in the future, and recover from the impacts of COVID-19.”
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, NVX-CoV2373
January 22, 2021 17:23 ET | Source: Novavax, Inc. Novavax, Inc. Gaithersburg, Maryland, UNITED STATES
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses. NVX-CoV2373 is currently in Phase 3 clinical development for the prevention of COVID-19.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
Novavax, Inc.January 15, 2021 GMT
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer. In this newly created role, Dr. Ukwu will lead global regulatory strategy and execution as well as the quality assurance function for the company’s development-stage vaccine candidates, including its recombinant protein-based COVID-19 candidate vaccine, NVX-CoV2373.